scholarly journals Human Glandular Kallikrein

2020 ◽  
Author(s):  
Keyword(s):  
Glandular Kallikrein

Temporal variations of glandular kallikrein, protein and amylase in mixed human saliva

1987 ◽  
Vol 32 (10) ◽  
pp. 757-759 ◽  
Author(s):  
Joyce W. Jenzano ◽  
C.K. Brown ◽  
Sally M. Mauriello
Keyword(s):  
Temporal Variations ◽  
Human Saliva ◽  
Glandular Kallikrein

Sensitive two-site immunoassays for measurement of the free and total forms of human glandular kallikrein 2 (hK2)

2002 ◽  
Vol 1 (1) ◽  
pp. 96
Author(s):  
Ville Väisänen ◽  
S. Eriksson ◽  
K. Ivaska ◽  
H. Lilja ◽  
K. Pettersson
Keyword(s):  
Glandular Kallikrein ◽  
Kallikrein 2

DISCRIMINATION OF MEN WITH PROSTATE CANCER FROM THOSE WITH BENIGN DISEASE BY MEASUREMENTS OF HUMAN GLANDULAR KALLIKREIN 2 (HK2) IN SERUM

2000 ◽  
Vol 163 (1) ◽  
pp. 311-316 ◽  
Author(s):  
CHARLOTTE BECKER ◽  
TIMO PIIRONEN ◽  
KIM PETTERSSON ◽  
THOMAS BJöRK ◽  
KIRK J. WOJNO ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Disease ◽  
Glandular Kallikrein ◽  
Kallikrein 2

Glandular Kallikrein, Renin and Angiotensin Converting Enzyme of Diabetic and Hypertensive Rats

1989 ◽  
pp. 443-448 ◽  
Author(s):  
Hiroshi Handa ◽  
Shoki Sakurama ◽  
Shoichi Nakagawa ◽  
Taro Yasukouchi ◽  
Wataru Sakamoto ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Converting Enzyme ◽  
Hypertensive Rats ◽  
Glandular Kallikrein

Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue

Urology ◽  
2000 ◽  
Vol 56 (3) ◽  
pp. 527-532 ◽  
Author(s):  
Angeliki Magklara ◽  
Andreas Scorilas ◽  
Carsten Stephan ◽  
Glen O Kristiansen ◽  
Steffen Hauptmann ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Prostatic Tissue ◽  
Glandular Kallikrein ◽  
Kallikrein 2

scholarly journals Human Glandular Kallikrein in Breast Milk, Amniotic Fluid, and Breast Cyst Fluid

1999 ◽  
Vol 45 (10) ◽  
pp. 1774-1780 ◽  
Author(s):  
Angeliki Magklara ◽  
Andreas Scorilas ◽  
Carlos López-Otín ◽  
Francisco Vizoso ◽  
Alvaro Ruibal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Amniotic Fluid ◽  
Biological Fluids ◽  
Cyst Fluid ◽  
Cystic Disease ◽  
Breast Cyst Fluid ◽  
Breast Cyst ◽  
Glandular Kallikrein ◽  
Female Breast

Abstract Background: Human glandular kallikrein (hK2) belongs to the serine protease family of enzymes and has high sequence homology with prostate-specific antigen (PSA). The physiological role of hK2 has not as yet been determined, but there is evidence that it can regulate the proteolytic activity of PSA through processing and activating pro-PSA, an inactive precursor. Thus, it is conceivable that these two secreted proteins may coexist in biological fluids. Currently, hK2 is considered an androgen-regulated and prostate-specific protein. Recently, it has been demonstrated that hK2 is expressed in the breast cancer cell line T-47D after stimulation by steroid hormones, and we reported that hK2 can be detected in a subset of breast tumor extracts. These data suggest that hK2 may be expressed in tissues other than the prostate, such as those in which PSA has already been detected. Because hK2 is a secreted protein, it may be present in various biological fluids. Methods: We analyzed milk samples from lactating women, amniotic fluid from pregnant women, and breast cyst fluid from patients with gross breast cystic disease, using a highly sensitive and specific immunoassay for hK2. Results: hK2 was present in all three biological fluids. We suggest that the female breast may produce hK2 and provide evidence that hK2 may have value as an additional marker for the discrimination between type I and type II breast cysts. Conclusions: The female breast produces hK2 in addition to PSA. More studies are necessary to establish the role of this kallikrein in nondiseased breast, gross breast cystic disease, and breast cancer.

scholarly journals The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA

1999 ◽  
Vol 45 (11) ◽  
pp. 1960-1966 ◽  
Author(s):  
Angeliki Magklara ◽  
Andreas Scorilas ◽  
William J Catalona ◽  
Eleftherios P Diamandis
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Prostate Specific Antigen ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Prostatic Hyperplasia ◽  
Free Psa ◽  
Glandular Kallikrein ◽  
Total Psa

Abstract Background: Prostate-specific antigen (PSA) is the most reliable tumor marker available and is widely used for the diagnosis and management of prostate cancer. Unfortunately, PSA cannot distinguish efficiently between benign and malignant disease of the prostate, especially within the range of 4–10 μg/L. Among the refinements developed to enhance PSA specificity is the free/total PSA ratio, which is useful in discriminating between the two diseases within the diagnostic “gray zone”. Recent data indicate that human glandular kallikrein (hK2), a protein with high homology to PSA, may be an additional serum marker for the diagnosis and monitoring of prostate cancer. Methods: We analyzed 206 serum samples (all before treatment was initiated) from men with histologically confirmed benign prostatic hyperplasia (n = 100) or prostatic carcinoma (n = 106) with total PSA in the range of 2.5–10 μg/L. Total and free PSA and hK2 were measured with noncompetitive immunological procedures. Statistical analysis was performed to investigate the potential utility of the various markers or their combinations in discriminating between benign prostatic hyperplasia and prostatic carcinoma. Results: hK2 concentrations were not statistically different between the two groups of patients. There was a strong positive correlation between hK2 and free PSA in the whole patient population. hK2/free PSA ratio (area under the curve = 0.69) was stronger predictor of prostate cancer than the free/total PSA ratio (area under the curve = 0.64). At 95% specificity, the hK2/free PSA ratio identified 30% of patients with total PSA between 2.5–10 μg/L who had cancer. At 95% specificity, the hK2/free PSA ratio identified 25% of patients with total PSA between 2.5 and 4.5 μg/L who had cancer. Conclusions: Our data suggest that hK2 in combination with free and total PSA can enhance the biochemical detection of prostate cancer in patients with moderately increased total PSA concentrations. More specifically, the hK2/free PSA ratio appears to be valuable in identifying a subset of patients with total PSA between 2.5 and 4.5 μg/L who have high probability of cancer and who should be considered for biopsy.

Sign in / Sign up

Export Citation Format

Share Document